This invention relates to medicaments, particularly novel fused imidazolium derivatives useful for the treatment of cancers and novel synthetic intermediate compounds thereof.
The novel imidazolium derivatives fused with an aryl or heteroaryl ring, characterized in that the 1- and/or 3-position is substituted by an alkyl group etc. having a substituent selected from the group consisting of -ORa, -SRa and the like, have excellent anti-tumor activity and low toxicity and are useful as anticancer agents having wide margins of safety.
本发明涉及药物,特别是用于治疗癌症的新型融合
咪唑鎓衍
生物及其新型合成
中间体化合物。
与芳基或杂芳基环融合的新型
咪唑鎓衍
生物,其特征在于1位和/或3位被烷基等取代,该烷基的取代基选自-ORa、-SRa等组成的组,具有优异的抗肿瘤活性和低毒性,可用作抗癌剂,具有较宽的安全范围。